| Name | Title | Contact Details |
|---|
Enanta Pharmaceuticals is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Two protease inhibitors, glecaprevir and paritaprevir, discovered and developed through Enanta`s collaboration with AbbVie, have now been approved around the world as part of AbbVie`s regimens for the treatment of hepatitis C virus (HCV) infection. The leading regimen is sold under the tradenames MAVYRETâ„¢ (U.S.) and MAVIRETâ„¢ (ex-U.S.) (glecaprevir/pibrentasvir). Royalties from the AbbVie collaboration are helping to fund Enanta`s research and development efforts, which are currently focused on the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), SARS-CoV-2 (COVID-19) and human metapneumovirus (hMPV).
BHE is an independent health analytics company with over two decades of experience in designing and conducting research that assesses the value of medical technologies.
Silicycle is a Quí©bec, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Pro Med Pharmacies, Inc is a Amarillo, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.